Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
University of Utah
ClinicalTrials.gov Identifier:
NCT01614184
First received: March 6, 2012
Last updated: July 8, 2013
Last verified: July 2013
  Purpose

The study goal is to develop a new method of intraoperative lymphatic mapping with fluorescent contrast agents to improve the outcome of therapeutic breast cancer surgery.


Condition Intervention Phase
Breast Cancer
Drug: Fluorescein
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Operable Breast Cancer

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • Sentinel Lymph node (SLN) detection [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    Ability of peri-areolar or peri-tumoral fluorescein to detect SLNs in patients with operable breast cancer.


Secondary Outcome Measures:
  • Fluorescence detection [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    To evaluate the ability to detect fluorescein fluorescence transdermally with a fluorometer.

  • Correlation between two radiation intensities [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    To evaluate if there is a correlation between SLN ex-vivo fluorescent intensity and SLN ex-vivo gamma radiation intensity.

  • Correlation between intensity and metastasis [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    To evaluate if there is a correlation between SLN ex-vivo fluorescent intensity and SLN metastasis.

  • Fluorescence detection after processing [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    To evaluate if fluorescein fluorescence can be detected in the SLN after fixation and histological processing.

  • Number of patients with adverse events [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
    To evaluate the safety of peri-areolar or peri-tumoral fluorescein injections.


Enrollment: 0
Study Start Date: May 2008
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All patients
All patients enrolled in study.
Drug: Fluorescein
Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
Other Name: Fluorescite®

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patient
  • Ability to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.
  • Between 18 and 90 years of age.
  • Have been diagnosed with invasive adenocarcinoma, or high-grade ductal carcinoma in-situ. If a core or open biopsy is done, it must demonstrate invasive adenocarcinoma. If only a FNA is done, it must be positive and accompanied by a positive clinical breast examination and ultrasound or mammography. The tumor must be operable.
  • Clinically negative lymph nodes.
  • Must have had a bilateral mammogram within a year of enrollment.
  • The interval between the initial cytologic or histologic diagnosis of breast cancer and enrollment must be no more than 60 days.
  • ECOG performance status 0-1
  • Patients in whom the diagnosis of breast cancer has been obtained utilizing fine needle aspiration cytology or core needle biopsy are preferred. However, patients who are diagnosed by open biopsy procedures are eligible.
  • Patients with prior excisional biopsy or lumpectomy are eligible for entry.
  • Patients with prior non-breast malignancies are eligible if they have been disease free for 5 years before enrollment. Patients with squamous or basal cell carcinoma of the skin that has been effectively treated, carcinoma in situ of the cervix that has been treated by operation only, or LCIS of the ipsilateral or contralateral breast treated by surgery only are eligible, even if these conditions were diagnosed within 5 years before enrollment onto this study.

Exclusion Criteria:

  • Male patient
  • Ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude. (Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration. Patients with these latter to conditions are eligible.)
  • One or more ipsilateral axillary lymph nodes that are positive for tumor on clinical examination.
  • Bilateral malignancy or a mass in the opposite breast that is suspicious for malignancy, unless a biopsy proves that the mass is not malignant.
  • Previous removal of any ipsilateral axillary lymph node.
  • Diffuse tumors or multiple malignant tumors in different quadrants of the breast.
  • Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes. Patients with these conditions are considered ineligible unless there is biopsy evidence that these are not involved with tumor.
  • Patients with any prior breast malignancy other than LCIS.
  • Prior treatment for this breast cancer including irradiation, chemotherapy, immunotherapy, and/or hormonal therapy.
  • Allergy to radiocolloid or fluorescein.
  • Inability to localize SLN drainage basins via lymphatic mapping. (e.g., no basin found which emits gamma-radiation after injection with technetium -99)
  • Organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that might preclude participation in the protocol, or be exacerbated by therapy.
  • Breast cancer related operative procedures not corresponding to criteria described in the protocol.
  • Primary or secondary immune deficiencies or known significant autoimmune disease which would pose a risk to the participant based on the physician's judgment.
  • History of organ transplantation.
  • Pregnant or lactating women.
  • Participation in concurrent experimental protocols or alternative therapies that might confound the analysis of this trial.
  • Nonmalignant systemic disease (e.g., cardiovascular, renal, hepatic, etc.) that precludes a patient from being subjected to any of the treatment options or that would prevent prolonged follow-up based on the physician's judgment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT01614184     History of Changes
Other Study ID Numbers: HCI23922
Study First Received: March 6, 2012
Last Updated: July 8, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 28, 2014